NLRP3-IN-76 

NLRP3-IN-76 is an orally active NLRP3 inhibitor. NLRP3-IN-76 inhibits the production of NO, and the mRNA levels of proinflammatory cytokines (iNOS, IL-6, IL-1β and TNFα). NLRP3-IN-76 shows anti-inflammatory effects by inhibiting the activation of the NLRP3 inflammasome and NF-κB signaling pathway. NLRP3-IN-76 ameliorates DSS (HY-116282C)-induced colitis and can be used for research of inflammatory bowel diseases (IBD)^[1].

NLRP3-IN-76 (Compound ST12) (10 μM, 24 h) inhibits nitric oxide (NO) production (52.67%) in LPS induced RAW264.7 cells^[1].
NLRP3-IN-76 (10 μM, 24 h) inhibits mRNA levels of proinflammatory cytokines in LPS-stimulated RAW264.7 cells, such as inducible NO synthase (iNOS), IL-6, IL-1β and TNF-α^[1].
NLRP3-IN-76 (2.5-10 μM, 24 h) inhibits NLRP3 inflammasome activation and NF-κB signaling pathway in LPS-stimulated RAW264.7 cells ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

NLRP3-IN-76 (Compound ST12) (35 mg/kg, i.g., 9 days) protects mice from DSS-induced colitis by inhibiting the in vivo activation of NLRP3 inflammasome^[1].
NLRP3-IN-76 (100-400 mg/kg, p.o.) is well-tolerated in the C57 mice (LD₅₀: 300 mg/kg)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

338.32

C₁₇H₁₄N₄O₄

COC1=CC=C(C2=NC(C(NNC(C3=NC=CC=C3)=O)=O)=CO2)C=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Sun Z, et al. Discovery of novel Bis-amide analogue ST12 for the treatment of inflammatory bowel diseases (IBD) by inhibiting NLRP3 inflammasome activation. Bioorg Chem. 2025 Jun 1;159:108402.